Dr. Alessi et al., PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO, The Journal of biological chemistry, 270(46), 1995, pp. 27489-27494
PD 098059 has been shown previously to inhibit the dephosphorylated fo
rm of mitogen-activated protein kinase kinase-1 (MAPKK1) and a mutant
MAPKK1(S217E,S221E), which has low levels of constitutive activity (Du
dley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A.
R. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 7686-7689), Here we report
that PD 098059 does not inhibit Raf-activated MAPKK1 but that it prev
ents the activation of MAPKK1 by Raf or MEK kinase in vitro at concent
rations (IC50 = 2-7 mu M) similar to those concentrations that inhibit
dephosphorylated MAPK1 or MAPKK1(S217E,S221E). PD 098059 inhibited th
e activation of MAPKK2 by Raf with a much higher IC50 value (50 mu M)
and did not inhibit the phosphorylation of other Raf or MEK kinase sub
strates, indicating that it exerts its effect by binding to the inacti
ve form of MAPKK1. PD 098059 also acts as a specific inhibitor of the
activation of MAPKK in Swiss 3T3 cells, suppressing by 80-90% its acti
vation by a variety of agonists, The high degree of specificity of PD
098059 in vitro and in vivo is indicated by its failure to inhibit 18
protein Ser/Thr kinases (including two other MAPKK homologues) in vitr
o by its failure to inhibit the in vivo activation of MAPKK and MAP ki
nase homologues that participate in stress and interleukin-1-stimulate
d ki nase cascades in KB and PC12 cells, and by lack of inhibition of
the activation of p70 S6 kinase by insulin or epidermal growth factor
in Swiss 3T3 cells. PD 098059 (50 mu M) inhibited the activation of p4
2(MAPK) and isoforms of MAP kinase-activated protein kinase-1 in Swiss
3T3 cells, but the extent of inhibition depended on how potently c-Ra
f and MAPKK were activated by any particular agonist and demonstrated
the enormous amplification potential of this kinase cascade, PD 098059
not only failed to inhibit the activation of Raf by platelet-derived
growth factor, serum, insulin, and phorbol esters in Swiss 3T3 cells b
ut actually enhanced Raf activity, The rate of activation of Raf by pl
atelet derived growth factor was increased 3-fold, and the subsequent
inactivation that occurred after 10 min was prevented, These results i
ndicate that the activation of Raf is suppressed and that its inactiva
tion is accelerated by a downstream component(s) of the MAP kinase pat
hway.